Parke Bancorp, the holding company for Parke Bank, has appointed Michael L. Regina, a seasoned entrepreneur with over 20 years of experience in business leadership and commercial real estate development, to its Board of Directors. Regina is co-founder of Big Sky Enterprises and Global Post Auditing Solutions, bringing valuable expertise in real estate, finance, and operational management. His appointment is expected to enhance the bank's strategic direction, especially given his strong community ties in South Jersey and South Carolina. Parke Bancorp operates in New Jersey and South Carolina, serving individuals and businesses with a range of financial services.
Parke Bancorp's recent board appointment is noted alongside a Financials-sector market breadth of 39 advancing and 46 declining stocks out of 85 on Pluang. Among these, Lufax Holding Ltd (LU) gained 13.11% to USD 1.38 with a typical hold time of 12 days and a buy order activity of 58%. Apollo Global Management (APO) traded at USD 120.04, down 3.47%, with a 66-day hold time and 100% buy order activity. Affirm Holdings Inc (AFRM) rose 3.42% to USD 70.42 with a 21-day typical hold time, as of Sep 25, 2026 01:11 WIB.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
